Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 236182, 11 pages
http://dx.doi.org/10.1155/2014/236182
Research Article

CNB-001 a Novel Curcumin Derivative, Guards Dopamine Neurons in MPTP Model of Parkinson’s Disease

1Department of Biotechnology, Periyar University, Salem, Tamilnadu 636011, India
2Pharmacology Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh 226031, India

Received 27 February 2014; Accepted 14 May 2014; Published 17 June 2014

Academic Editor: Arianna Scuteri

Copyright © 2014 Richard L. Jayaraj et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Jankovic, “Parkinson's disease: clinical features and diagnosis,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 4, pp. 368–376, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. W. Dauer and S. Przedborski, “Parkinson's disease: mechanisms and models,” Neuron, vol. 39, no. 6, pp. 889–909, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. M. B. Spina and G. Cohen, “Dopamine turnover and glutathione oxidation: implications for Parkinson disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 4, pp. 1398–1400, 1989. View at Google Scholar · View at Scopus
  4. R. E. Heikkila and P. K. Sonsalla, “The MTPT-treated mouse as a model of Parkinsonism: how good is it?” Neurochemistry International, vol. 20, supplement 1, pp. 299S–303S, 1992. View at Google Scholar · View at Scopus
  5. G. W. Miller, J. D. Erickson, J. T. Perez et al., “Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease,” Experimental Neurology, vol. 156, no. 1, pp. 138–148, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. A. H. Schapira, “Mitochondria in the aetiology and pathogenesis of Parkinson's disease,” The Lancet Neurology, vol. 7, no. 1, pp. 97–109, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Li, K. Ragheb, G. Lawler et al., “Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production,” The Journal of Biological Chemistry, vol. 278, no. 10, pp. 8516–8525, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. M. del Zompo, M. P. Piccardi, S. Ruiu, M. Quartu, G. L. Gessa, and A. Vaccari, “Selective MPP+ uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity,” British Journal of Pharmacology, vol. 109, no. 2, pp. 411–414, 1993. View at Google Scholar · View at Scopus
  9. R. Tintner and J. Jankovic, “Treatment options for Parkinson's disease,” Current Opinion in Neurology, vol. 15, no. 4, pp. 467–476, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. G. M. Cole, B. Teter, and S. A. Frautschy, “Neuroprotective effects of curcumin,” Advances in Experimental Medicine and Biology, vol. 595, pp. 197–212, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Liu, R. Dargusch, P. Maher, and D. Schubert, “A broadly neuroprotective derivative of curcumin,” Journal of Neurochemistry, vol. 105, no. 4, pp. 1336–1345, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Valera, R. Dargusch, P. A. Maher, and D. Schubert, “Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer's disease,” Journal of Neuroscience, vol. 33, no. 25, pp. 10512–10525, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. R. L. Jayaraj, K. Tamilselvam, T. Manivasagam, and N. Elangovan, “Neuroprotective effect of CNB-001, a novel pyrazole derivative of curcumin on biochemical and apoptotic markers against rotenone-induced SK-N-SH cellular model of Parkinson's disease,” Journal of Molecular Neuroscience, vol. 51, no. 3, pp. 863–870, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Antzoulatos, M. W. Jakowec, G. M. Petzinger, and R. I. Wood, “Sex differences in motor behavior in the MPTP mouse model of Parkinson's disease,” Pharmacology Biochemistry and Behavior, vol. 95, no. 4, pp. 466–472, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. Y.-S. Lau, L. Novikova, and C. Roels, “MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact,” Neuroscience Research, vol. 52, no. 4, pp. 371–378, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. O. Narumoto, Y. Matsuo, M. Sakaguchi et al., “Suppressive effects of a pyrazole derivative of curcumin on airway inflammation and remodeling,” Experimental and Molecular Pathology, vol. 93, no. 1, pp. 18–25, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Rozas, E. López-Martín, M. J. Guerra, and J. L. Labandeira-García, “The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism,” Journal of Neuroscience Methods, vol. 83, no. 2, pp. 165–175, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. J. L. Tillerson and G. W. Miller, “Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism,” Journal of Neuroscience Methods, vol. 123, no. 2, pp. 189–200, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. S. RajaSankar, T. Manivasagam, and S. Surendran, “Ashwagandha leaf extract: a potential agent in treating oxidative damage and physiological abnormalities seen in a mouse model of Parkinson's disease,” Neuroscience Letters, vol. 454, no. 1, pp. 11–15, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. K. B. J. Franklin and G. Paxinos, The Mouse Brain in Stereotaxic Coordinates, Academic Press, London, UK, 2007.
  21. A. Bhattacharya, S. Ghosal, and S. K. Bhattacharya, “Anti-oxidant effect of Withania somnifera glycowithanolides in chronic footshock stress-induced perturbations of oxidative free radical scavenging enzymes and lipid peroxidation in rat frontal cortex and striatum,” Journal of Ethnopharmacology, vol. 74, no. 1, pp. 1–6, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. D. J. Jollow, J. R. Mitchell, N. Zampaglione, and J. R. Gillette, “Bromobenzene induced liver necrosis. Protective role of glutathione and evidence for 3,4 bromobenzene oxide as the hepatotoxic metabolite,” Pharmacology, vol. 11, no. 3, pp. 151–169, 1974. View at Google Scholar · View at Scopus
  23. Y. Yamamoto and K. Takahashi, “Glutathione peroxidase isolated from plasma reduces phospholipid hydroperoxides,” Archives of Biochemistry and Biophysics, vol. 305, no. 2, pp. 541–545, 1993. View at Publisher · View at Google Scholar · View at Scopus
  24. L. W. Oberley and D. R. Spitz, “Assay of superoxide dismutase activity in tumor tissue,” Methods in Enzymology, vol. 105, pp. 457–464, 1984. View at Google Scholar · View at Scopus
  25. H. Aebi, “Catalase in vitro,” Methods in Enzymology, vol. 105, pp. 121–126, 1984. View at Publisher · View at Google Scholar · View at Scopus
  26. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the Folin phenol reagent,” The Journal of Biological Chemistry, vol. 193, no. 1, pp. 265–275, 1951. View at Google Scholar · View at Scopus
  27. G. C. Brown and V. Borutaite, “Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols,” Biochimica et Biophysica Acta: Bioenergetics, vol. 1658, no. 1-2, pp. 44–49, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. R. L. Jayaraj and N. Elangovan, “In vitro antioxidant potential and DNA protecting activity of CNB-001, a novel pyrazole derivative of curcumin,” Chronicles of Young Scientists, vol. 5, pp. 44–52, 2014. View at Publisher · View at Google Scholar
  29. T. Hanakawa, Y. Katsumi, H. Fukuyama et al., “Mechanisms underlying gait disturbance in Parkinson's disease. A single photon emission computed tomography study,” Brain, vol. 122, no. 7, pp. 1271–1282, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. S. J. Crocker, P. Liston, H. Anisman et al., “Attenuation of MPTP-induced neurotoxicity and behavioural impairment in NSE-XIAP transgenic mice,” Neurobiology of Disease, vol. 12, no. 2, pp. 150–161, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Fredriksson and T. Archer, “MPTP-induced behavioural and biochemical deficits: a parametric analysis,” Journal of Neural Transmission: Parkinson's Disease and Dementia Section, vol. 7, no. 2, pp. 123–132, 1994. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Thiffault, N. Aumont, R. Quirion, and J. Poirier, “Effect of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain,” Journal of Neurochemistry, vol. 65, no. 6, pp. 2725–2733, 1995. View at Google Scholar · View at Scopus
  33. S. Toffa, G. M. Kunikowska, B.-Y. Zeng, P. Jenner, and C. D. Marsden, “Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration,” Journal of Neural Transmission, vol. 104, no. 1, pp. 67–75, 1997. View at Publisher · View at Google Scholar · View at Scopus
  34. E. A. Fon, E. N. Pothos, B.-C. Sun, N. Killeen, D. Sulzer, and R. H. Edwards, “Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action,” Neuron, vol. 19, no. 6, pp. 1271–1283, 1997. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Anandhan, U. Janakiraman, and T. Manivasagam, “Theaflavin ameliorates behavioral deficits, biochemical indices and monoamine transporters expression against subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson's disease,” Neuroscience, vol. 218, pp. 257–267, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. K. R. Rekha, G. P. Selvakumar, S. Sethupathy, K. Santha, and R. I. Sivakamasundari, “Geraniol ameliorates the motor behavior and neurotrophic factors inadequacy in MPTP-induced mice model of Parkinson's disease,” Journal of Molecular Neuroscience, vol. 51, no. 3, pp. 851–862, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. Y.-M. Wang, R. R. Gainetdinov, F. Fumagalli et al., “Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine,” Neuron, vol. 19, no. 6, pp. 1285–1296, 1997. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Martinez-Vicente, Z. Talloczy, S. Kaushik et al., “Dopamine-modified α-synuclein blocks chaperone-mediated autophagy,” Journal of Clinical Investigation, vol. 118, no. 2, pp. 777–778, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. E. V. Mosharov, K. E. Larsen, E. Kanter et al., “Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons,” Neuron, vol. 62, no. 2, pp. 218–229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. J. M. Wilson, K. S. Kalasinsky, A. I. Levey et al., “Striatal dopamine nerve terminal markers in human, chronic methamphetamine users,” Nature Medicine, vol. 2, no. 6, pp. 699–703, 1996. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. Mizuno, S. Ohta, M. Tanaka et al., “Deficiencies in Complex I subunits of the respiratory chain in Parkinson's disease,” Biochemical and Biophysical Research Communications, vol. 163, no. 3, pp. 1450–1455, 1989. View at Google Scholar · View at Scopus
  42. W. D. Parker Jr., S. J. Boyson, and J. K. Parks, “Abnormalities of the electron transport chain in idiopathic Parkinson's disease,” Annals of Neurology, vol. 26, no. 6, pp. 719–723, 1989. View at Publisher · View at Google Scholar · View at Scopus
  43. P. A. Trimmer, R. H. Swerdlow, J. K. Parks et al., “Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines,” Experimental Neurology, vol. 162, no. 1, pp. 37–50, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Anglade, “Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging,” Histology and Histopathology, vol. 12, no. 3, pp. 603–610, 1997. View at Google Scholar · View at Scopus
  45. B. K. Binukumar, A. Bal, R. J. L. Kandimalla, and K. D. Gill, “Nigrostriatal neuronal death following chronic dichlorvos exposure: crosstalk between mitochondrial impairments, α synuclein aggregation, oxidative damage and behavioral changes,” Molecular Brain, vol. 3, no. 1, article 35, 2010. View at Publisher · View at Google Scholar · View at Scopus